Rumors

Google Tests New AI Agent To Take On OpenClaw With Advanced Task Automation: Report

Namrata Sen — Wed, 06 May 2026 09:44:09 +0000

Alphabet‘s Google (NASDAQ:GOOGL) (NASDAQ:GOOG) is reportedly developing an AI personal agent for its Gemini app, capable of performing tasks on behalf of the user.

Google is testing a new AI agent, internally named “Remy”. This agent operates within a staff-only version of Google’s Gemini app and can integrate with a range of Google’s other services, reported Business Insider on Tuesday, citing an internal document.

Remy is a 24/7 Gemini-powered AI agent that acts on users' behalf, handling tasks across work, school, and daily life, not just answering questions or generating content.

According to the report, AI agent appears to be more advanced than existing tools and has similarities to OpenClaw, an AI agent that gained popularity earlier this year for its ability to perform tasks such as responding to messages or conducting research for users.

While there is no confirmed timeline for Remy’s public launch, the document refers to ...

Full story available on Benzinga.com

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Vandana Singh — Wed, 22 Apr 2026 18:20:53 +0000

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion.

• Inhibrx Biosciences stock is challenging resistance. Why did INBX hit a new high?

The cancer-focused biotech is evaluating a potential joint spin-off of INBRX-106 alongside another early-stage oncology asset.

Reuters on Wednesday reported that if clinical trials are successful, the combined value of the two therapies could exceed $9 billion.

INBRX-106 Gains Attention For Keytruda Combination Potential

Interest has centered on INBRX-106, which is being tested both as a standalone therapy and in combination with Merck & Co. Inc.’s (NYSE:MRK) blockbuster immunotherapy, Keytruda (pembrolizumab).

The company plans to announce interim objective response rate data from the randomized Phase 2/3 trial in head and neck squamous cell carcinoma in combination with Keytruda in the second quarter of 2026, and progression-free survival data in the fourth quarter of 2026.

In March, Merck agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to offset ...

Full story available on Benzinga.com

Spirit Airlines Could Halt Operations Within Days As Fuel Costs Rise: Report

Badar Shaikh — Fri, 17 Apr 2026 09:42:42 +0000

Spirit Aviation Holdings Inc. (OTC:FLYYQ) could reportedly halt operations within days as the creditors raise doubts about the company’s ability to clear dues.

Spirit To Liquidate?

On Thursday, CBS News reported that the airline could halt its operations within the coming days, raising questions about the passengers who might have already booked their tickets on Spirit flights. The airline had earlier filed for bankruptcy amid post Covid-19 struggles.

Spirit Airlines didn’t immediately respond to Benzinga‘s request for comment.

The war in Iran has led to a surge in fuel costs, which is said to be the reason behind the reported liquidation. According to data from Airlines for America, the price of a gallon of jet fuel on Thursday was $4.32, which, while lower ...

Full story available on Benzinga.com